Skip to main content
. 2017 Feb 18;9(5):242–251. doi: 10.4254/wjh.v9.i5.242

Table 9.

Summary of studies with relatively large cohort of the patients who underwent hepatectomy for liver metastasis from genitourinary primary tumor

Disease Ref. Year Period No. of patients MST (mo) 3-ysr (%) 5-ysr (%) Factors associated with worse overall survival
Renal cell carcinoma Adam et al[10]1 2006 1983-2004 85 36 NR 38 NR
Thelen et al[52] 2007 1988-2006 31 48 54 39 Resection margin (R1,2)
Staehler et al[53] 2010 1995-2006 68 142 NR 62 High-grade primary renal cell carcinoma, performance status ≥ 1, lymph node status
Ruys et al[54] 2011 1990-2008 29 33 47 43 Synchronous metastases, R1,2 resection margin (univariate)
Hatzaras et al[55] 2012 1994-2011 43 Not reached 62 NR Disease-free interval ≤ 12 mo, exrahepatic disease (univariate)
Schiergens et al[16]1 2016 2003-2013 28 50 68 NR NR
Gyneclogic primary Kamel et al[56] 2011 1990-2010 52 53 57 41 NR
Ovarian cancer Merideth et al[57] 2003 1976-1999 262 26 NR NR Interval from the primary diagnosis < 12 mo, residual disease > 1 cm (univariate)
Adam et al[10]1 2006 1983-2004 65 98 NR 50 NR
Lim et al[58] 2009 2001-2008 142 Not reached NR 51 Hematogeneous liver metastasis < hepatic parenchymal metastasis from peritoneal seeding5
Neumann et al[59] 2012 1991-2007 41 42(R0 resection) NR NR R1,2 resection, pre-operative ascites, bilobular liver metastasis
Niu et al[60] 2012 2000-2011 60 39 NR 30 R1,2 resection
Kolev et al[61] 2014 1988-2012 273 56 NR NR Interval from the primary surgery ≤ 24 mo, residual disease ≥ 1 cm
Bacalbasa et al[62] 2015 2002-2014 3124 16 (metastasis from seeding), 13 (hematogeneous) NR NR No significant risk factor
Schiergens et al[16]1 2016 2003-2013 24 33 43 NR NR
Testicular cancer Hahn et al[63] 1999 1974-1996 57 NR 97 (2-yr) NR NR
Adam et al[10]1 2006 1983-2004 78 82 NR 51 NR
1

As a part of the report of on-colorectal non-neuroendocrine liver metastases;

2

As a part of debulking surgery;

3

Hepatectomy as secondary cytoreduction;

4

Including 2nd (n = 15), 3rd (3) and 4th (2) cytoreduction operations;

5

Only risk factors that included patients undergoing palliative treatment were reported. MST: Median survival time; ysr: Year survival rate; NR: Not reported.